Capricor Therapeutics (NASDAQ:CAPR) Raised to Strong-Buy at LADENBURG THALM/SH SH

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other research analysts have also recently issued reports on the company. B. Riley Financial lifted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Roth Mkm reissued a “buy” rating and set a $38.00 target price on shares of Capricor Therapeutics in a research note on Friday, May 15th. Piper Sandler reissued an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $50.30.

Capricor Therapeutics Stock Down 13.0%

Capricor Therapeutics stock opened at $26.44 on Thursday. The company’s 50 day moving average price is $30.00 and its two-hundred day moving average price is $28.41. Capricor Therapeutics has a 52 week low of $4.30 and a 52 week high of $40.37. The stock has a market cap of $1.53 billion, a P/E ratio of -11.40 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, equities analysts anticipate that Capricor Therapeutics will post -0.75 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $247,758.99. This represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 173,429 shares of company stock worth $5,329,440 over the last ninety days. Corporate insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently added to or reduced their stakes in CAPR. Creek Drive Management Group LLC acquired a new stake in Capricor Therapeutics during the 4th quarter valued at $1,039,000. Moody Aldrich Partners LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at $6,025,000. Pier Capital LLC boosted its stake in Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after purchasing an additional 128,837 shares in the last quarter. UBS Group AG lifted its stake in shares of Capricor Therapeutics by 91.0% during the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock valued at $6,875,000 after acquiring an additional 113,499 shares during the period. Finally, HBK Sorce Advisory LLC increased its stake in shares of Capricor Therapeutics by 19.4% in the 4th quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock valued at $5,879,000 after acquiring an additional 33,128 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.